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Severe and Refractory Peptic Ulcer Disease:
The Diagnostic Dilemma
Case Report and Comprehensive Review
JAMES L. GUZZO, MD, MONA DUNCAN, MD, BARBARA L. BASS, MD,
GRANT V. BOCHICCHIO, MD, MPH, and LENA M. NAPOLITANO, MD
The recognition of Helicobacter pylori infection as a cause of peptic ulcer disease, medical regimens
to eradicate the organism, and the widespread use of proton pump inhibition to suppress gastric acid
secretion have revolutionized the management of peptic ulcer disease. As a result, successful medical
management of peptic ulcer disease has largely supplanted the need for gastric surgery by general
surgeons. Surgery is reserved for complications of the disease, refractory disease, or rare causes
of ulcer disease such as gastrinoma and Zollinger–Ellison syndrome. In this report, we describe a
case of intractable peptic ulcer disease that progressed to gastric outlet obstruction despite maximal
medical therapy. We review the diagnostic studies utilized to evaluate the potential etiologies of
peptic ulcer disease and the difficulty in diagnosing gastrinoma and Zollinger–Ellison in the setting
of potent medical acid suppression therapy.
KEY WORDS: peptic ulcer disease; Helicobacter pylori; gastrin; Zollinger–Ellison syndrome; hypersecretion.
Regimens to identify and eradicate Helicobacter pylori
infection and the widespread use of proton pump inhi-
bition to suppress gastric acid secretion have resulted in
successful medical management of peptic ulcer disease in
the vast majority of patients (1–3). Surgical management
of peptic ulcer disease is now limited to treatment of more
emergent complications of the disease (hemorrhage, per-
foration, gastric outlet obstruction), intractability, and rare
causes of ulcer disease such as gastrinoma and Zollinger–
Ellison Syndrome (ZES). Indications for elective peptic
ulcer surgery include resection of ulcers suspicious for
malignancy, failure to heal despite maximal medical ther-
apy, intolerance or noncompliance with medical therapy,
and relapse while on maximal medical therapy. In this re-
port we describe a patient with persistent abdominal pain,
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nausea, and emesis from intractable peptic ulcer disease
that progressed despite maximal medical therapy.
CASE REPORT
A 43-year-old female was evaluated at the Gastroenterology
Clinic for persistent epigastric abdominal pain related to a known
duodenal ulcer. Her medical history was notable for heavy to-
bacco use, prior alcohol use, and a history of depression. Her
epigastric pain had been present for 20 years but had worsened
over the past 5 years, and pain was unrelated to meals. Despite
warnings against it, she intermittently used nonsteroidal anti-
inflammatory medication (NSAIDs) for pain control. She had
been treated twice previously for Helicobacter pylori infection.
Diagnostic esophagogastroduodenoscopy (EGD), H. pylori
antigen testing, and computed tomography of the abdomen and
pelvis were performed. EGD revealed a single, nonbleeding su-
perficial ulcer in the gastric antrum, extending to the pylorus,
and a large duodenal bulb ulcer. Tissue biopsy was taken for
Campylobacter-like organism (CLO) testing to identify the pres-
ence of H. pylori, and separate biopsies to rule out carcinoma
were all negative. Repeat blood testing for H. pylori was neg-
ative at this time. CT scan of the abdomen and pelvis demon-
strated antral and pyloric wall thickening but no adjacent masses
or lymphadenopathy. Acid suppression therapy with a proton
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pump inhibitor (PPI) was increased (rabeprazole, 40 mg po bid)
and the patient was scheduled for an interval EGD in 8 weeks to
assess ulcer healing.
She returned to the emergency department 2 weeks later with
a complaint of 24 hr of increasing epigastric pain, nausea, and
emesis. She did report one episode of a small amount of coffee
ground emesis; nasogastric lavage was negative. She was admit-
ted to the medicine service, made NPO, and started on intra-
venous PPI therapy, and intravenous antiemetics and analgesics
were administered as needed. EGD again confirmed the prepy-
loric ulcer, with no evidence of interval healing or stigmata of
recent bleeding. A new finding was a severely strictured, friable
region in the distal bulb that would not permit the endoscope to
pass. A general surgery consult was obtained for evaluation of
gastric outlet obstruction.
The evaluation of the etiology of the severe peptic ulcer dis-
ease in this patient included multiple diagnostic studies. An up-
per gastrointestinal (GI) series was performed to evaluate gastric
empyting, and radiographically demonstrated a linear ulceration
of the prepyloric area, normal duodenal caliber distal to ulcera-
tion, no constricting lesions, and normal emptying distal to ulcer.
Fasting gastrin level, neuroendocrine markers, and octreotide
scan were performed for evaluation of gastrinoma or ZES as a
cause of intractable peptic ulcer disease. Fasting gastrin level was
within normal range (37 pg/ml; normal, 0–42 pg/ml), but a gas-
trin level obtained 1 week prior was elevated at 115 pg/ml. Pan-
creatic polypeptide and chromogranin level A were also tested
and were in the normal range.
Since PPIs and H. pylori are major causes of hypergastrine-
mia, it is difficult to determine the meaning of a high fasting
serum gastrin concentration and to rule out ZES in these pa-
tients, in which case the surgical therapy would be altered. To
obtain a more accurate fasting gastrin, a plan to discontinue PPI
therapy and convert to high-dose histamine receptor antagonist
(ranitidine, 450 mg every 6 hr) for 10 days was initiated. At this
point, ranitidine would be held for 30 hr, and repeat fasting gas-
trin level and EGD performed. If the serum gastrin was elevated
in the face of an acidic pH in the gastric lumen, then this would
be more suggestive of a gastrinoma. An octreotide scan was also
scheduled. The patient did achieve some pain relief and needed
to leave to attend to personal matters; a PICC line was placed for
home TPN support, a date for interval endoscopy was set, and
plans were made for elective gastric surgery in 4 weeks.
The patient returned to the emergency department, 10 days
following discharge, with continued epigastric pain, nausea, and
emesis related to ingestion of solid foods. She stated that she used
NSAIDs when the oral narcotics worsened her nausea. She was
admitted to the general surgery service. Repeat EGD revealed a
gastric pH of 4 and gastric outlet obstruction. Laparotomy con-
firmed a large postpyloric duodenal ulcer eroding into the pan-
creas. Distal to this lesion there was complete obstruction of the
duodenum secondary to cicatrisation. Truncal vagotomy, antrec-
tomy, Roux-en-Y gastrojejunostomy, and cholecystectomy were
performed. Postoperative surgical pathology revealed the stom-
ach and proximal duodenum with moderate acute and chor-
nic inflammation, ulceration, fibrosis, and granulation tissue,
with focal intestinal metaplasia present in the gastric epithe-
lium. There was no evidence of H. pylori and no evidence of
malignancy.
The patient’s postoperative course was complicated by
catheter-related fungemia (Candida albicans) associated with
the use of total parenteral nutrition and C. difficile colitis. At her
2-month follow-up visit, she continued to have mild diarrhea, but
her upper GI symptoms fully resolved and she was tolerating a
postgastrectomy diet.
DISCUSSION
The management of peptic ulcer disease has changed
markedly over the last decade. The widespread use of
effective antisecretory therapies, including PPIs, and the
recognition and successful eradication of Helicobacter py-
lori infection have made this a disease that can be cured
by medical management in most cases (4). Surgical in-
tervention had once been the dominant form of definitive
therapy, but is now reserved for emergent, life-threatening
complications of peptic ulcer disease such as bleeding,
perforation, and obstruction (5). Intractability, failure to
comply with or tolerate medical therapy, and rare cases of
gastrinoma or ZES are indications for elective surgery for
peptic ulcer disease.
Helicobacter pylori is associated with 95% of duode-
nal and 70% of gastric ulcers, and eradication of H. pylori
reduces the relapse rate of ulcers. A recent Cochrane
evidence-based review of 53 randomized controlled trials
of short- and long-term treatment of peptic ulcer disease
in H. pylori-positive adults examined the magnitude of
this effect. Patients received at least 1 week of H. pylori
eradication compared with ulcer-healing drug, placebo, or
no treatment. In duodenal ulcer healing, H. pylori eradi-
cation therapy was superior to ulcer-healing drug (34 tri-
als, 3910 patients; relative risk [RR] of ulcer persisting =
0.66; 95% confidence interval [CI] = 0.58, 0.76) and no
treatment (2 trials, 207 patients; RR = 0.37; 95% CI =
0.26, 0.53). In gastric ulcer healing, no significant dif-
ferences were detected between eradication therapy and
ulcer-healing drug (13 trials, 1469 patients; RR = 1.32;
95% CI = 0.92, 1.90). This confirmed that a 1- to 2-week
course of H. pylori eradication therapy is an effective treat-
ment for H. pylori-positive peptic ulcer disease (6).
Furthermore, it is well accepted that in patients with
uncomplicated peptic ulcers, H. pylori eradication ther-
apy does not need to be followed by subsequent antisecre-
tory treatment. A recent 5-year, prospective, controlled
study randomized 82 patients with H. pylori-associated
bleeding peptic ulcers to one of four 16-week mainte-
nance treatment groups after successful H. pylori eradica-
tion with a 1-week PPI-based triple therapy and an addi-
tional 3-week treatment with 20 mg of omeprazole daily
for ulcer healing. The four experimental groups were as
follows: Group A received 15 ml of an antacid suspen-
sion four times daily; group B received 300 mg of col-
loidal bismuth subcitrate four times daily; group C re-
ceived 20 mg of famotidine twice daily; and group D, the
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control group, received placebo twice daily. Follow-up in-
cluded a urea breath test labeled with carbon-13, biopsy-
based tests, and repeat endoscopic examination. During a
mean follow-up of 56 months, there was no peptic ulcer
recurrence among the three treatment groups, and all of
the patients remained free of H. pylori infection during the
study period. This study documented that in patients with
bleeding peptic ulcers, antiulcer maintenance treatment
was not necessary to prevent ulcer recurrence after suc-
cessful H. pylori eradication and ulcer healing. In addition,
the 1-week PPI-based triple therapy had the efficacy to en-
sure long-term eradication of H. pylori in a region of high
prevalence (7).
Patients with complicated and/or refractory peptic ulcer
disease are the more challenging patients to evaluate and
treat. A recent analysis regarding admission rates for pep-
tic ulcer disease in the United Kingdom during 1972–2000
determined that emergency admission rates as a whole
changed little, a decline in the young being offset by an
increase in the elderly. Hemorrhage was the most com-
mon reason (approximately 115 per million population
for duodenal ulcer and 87 per million for gastric ulcer)
throughout (compared with perforation [80 and 21] and
pain [90 and 68]) (8).
This case report illustrates, however, the difficulties en-
countered in the diagnostic evaluation of patients with
refractory peptic ulcer disease. Potential etiologies of per-
sistent or worsening peptic ulcer disease include the fol-
lowing: patient risk factors and noncompliance, persistent
H. pylori infection, and non-H. pylori-related infection,
related to underlying idiopathic gastric hypersecretion, or
ZES and gastrinoma (Figure 1). Recent data and studies
regarding each of these potential etiologies of refractory
peptic ulcer disease are reviewed below.
Fig 1. Algorithm in the diagnostic workup of refractory peptic ulcer disease (PUD). H. pylori, Helicobacter pylori; PPI, proton pump
inhibitor; NSAIDs, nonsteroidal anti-inflammatory drugs.
Patient Risk Factors and Noncompliance
Although curative treatment of H. pylori infection
markedly reduces the relapse of peptic ulcers, the ulcers
that do recur have not been well characterized until re-
cently. A multicenter study involving 4940 peptic ulcer
patients who were H. pylori negative after successful erad-
ication treatment were followed for up to 48 months. The
crude peptic ulcer recurrence rate was 3.02% (149/4940).
The annual recurrence rates of gastric, duodenal, and gas-
troduodenal ulcer were 2.3%, 1.6%, and 1.6%, respec-
tively. Exclusion of patients who took NSAIDs produced
annual recurrence rates of 1.9%, 1.5% and 1.3%, respec-
tively. The recurrence rate was significantly higher in
gastric ulcer. Recurrence rates of patients who smoked,
consumed alcohol, and used NSAIDs were significantly
higher in those with gastric ulcer recurrence compared to
duodenal ulcer recurrence, and relapsed ulcers recurred at
the same site as, or sites adjacent to, the previous ulcers (9).
Persistent or recurrent peptic ulcer disease may occur
due to specific patient risk factors or noncompliance with
medical therapies. Patient risk factors for peptic ulcer
disease include smoking or alcohol use, stress, and use
of NSAIDs (10). A population-based prospective cohort
study (n = 2416 Danish adults) confirmed that the main
risk factors for peptic ulcer disease were H. pylori in-
fection (odds ratio [OR], 4.3; 95% CI, 2.2–8.3), tobacco
smoking (OR, 3.8; CI, 1.7–9.8), and stress with use of mi-
nor tranquilizers (OR, 3.0; CI, 1.4–6.6). In patients with
documented H. pylori, tobacco and alcohol use both in-
creased the risk of peptic ulcer disease, whereas moderate
leisure-time physical activity protected against peptic ul-
cer disease in Danish adults (11).
Multiple studies support a causal relationship between
smoking and peptic ulcers in men and women. A CDC
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study (the First National Health and Nutrition Examina-
tion Survey Epidemiologic Follow-up Study) used data
from a nationally representative prospective study of U.S.
adults to evaluate the impact of smoking on the incidence
of peptic ulcers in women (n = 2851) who had not been
diagnosed as having a peptic ulcer prior to the baseline in-
terview (12). Among these women, 140 (4.9%) developed
peptic ulcer disease. During 12.5 years of follow-up, the
estimated cumulative incidence of ulcers was 10.0% for
current smokers, 6.4% for former smokers, and 5.4% for
never smokers. After adjusting for age, education, regular
aspirin use, coffee consumption, and use of alcohol, cur-
rent smokers were 1.8 times more likely to develop ulcers
than never smokers (95% CI, 1.2 to 2.6); the risk of peptic
ulcer increased as the amount smoked increased.
Since tobacco use and alcohol use are independent risk
factors for peptic ulcer disease, and interfere with patient
compliance and rate of ulcer healing, cessation should
be considered in patients with refractory or severe peptic
ulcer disease (13).
NSAIDs are widely used for their anti-inflammatory,
analgesic, and antipyretic effects, and low-dose aspirin
(also an NSAID) is used for cardiovascular prophylaxis.
The main concern limiting use of these drugs is their GI
toxicity. GI side effects include ulcers (found at endoscopy
in 15%–30% of patients using NSAIDs regularly), com-
plications such as upper GI bleeding (annual incidence
of 1.0%–1.5%), and development of upper GI symptoms
such as dyspepsia (occurring in up to 60% of patients tak-
ing NSAIDs). Histamine-2 receptor antagonists (H2RAs)
are not effective at preventing NSAID-induced gastric ul-
cers when used at standard doses, although they can de-
crease upper GI symptoms. Misoprostol effectively de-
creases NSAID-induced ulcers and GI complications but
is used infrequently in the United States—perhaps because
of issues of compliance (multiple daily doses) and side ef-
fects (e.g., diarrhea, dyspepsia). Once-daily PPI therapy
also decreases the development of NSAID-associated ul-
cers and recurrent NSAID-related ulcer complications; it
also decreases upper GI symptoms in NSAID users. In
patients using aspirin, the addition of a cyclooxygenase-
2-specific inhibitor appears to significantly increase GI
risk to the level with a nonselective NSAID; aspirin plus
a nonselective NSAID appears to increase GI risk still
higher. Patients taking low-dose aspirin who have risk fac-
tors for GI complications (including concomitant nonse-
lective NSAID therapy) should therefore receive medical
cotherapy, such as a PPI (14).
Clinical trials have reproducibly demonstrated that the
healing of NSAID-associated gastric and duodenal ul-
cers is accelerated with the use of acid suppressive agents
(e.g., H2RAs and PPIs), even with the continued use of
the NSAID. The risk of developing gastroduodenal ulcers
or ulcer complications with the continued and long-term
use of NSAIDs is now well recognized as an important
problem commonly encountered in daily clinical practice.
Clinical trials have shown that coprescription of misopros-
tol, high-dose H2RAs or PPIs can effectively prevent or
reduce the rate of gastroduodenal mucosal damage asso-
ciated with the use of nonselective NSAIDs. Approaching
the problem in a different way, COX-2-selective inhibitors
circumvent the problem; based on their mechanism of ac-
tion, these agents are less ulcerogenic in the upper GI tract
compared with nonselective NSAIDs (15).
Most recently, a study examined whether prophylaxis
with lansoprazole could prevent relapse of ulcers after
eradication of H. pylori in patients with NSAID-related
peptic ulcers. Patients who presented with peptic ulcers
and were found to be infected with H. pylori while re-
ceiving NSAIDs were recruited into the study. They re-
ceived 30 mg lansoprazole, 1 g amoxicillin, and 500 mg
clarithromycin twice daily for 1 week, followed by 30 mg
lansoprazole daily for 4 weeks. Patients with healed ulcers
and H. pylori eradicated were given naproxen, 750 mg
daily, and randomly assigned to receive lansoprazole,
30 mg daily, or no treatment for 8 weeks. At the end of
the 8-week treatment period, significantly fewer patients
(1/22; 4.5%; 95% CI, 0–23) in the lansoprazole group
compared with the group that received H. pylori eradi-
cation alone (9/21; 42.9%; 95% CI, 22–66) developed re-
currence of symptomatic and complicated ulcers (log rank
test, P = 0.0025). Lansoprazole significantly reduced the
cumulative relapse of symptomatic and complicated ul-
cers in patients requiring NSAIDs after eradication of
H. pylori (16).
While a tremendous amount of research supports the
use of preventive therapies and interventions to reduce
and/or avoid NSAID- or aspirin-associated ulcers and ul-
cer complications in the upper GI tract, these strategies
are often underutilized, not optimally dosed, and/or asso-
ciated with poor patient compliance. This reinforces the
need for continued clinician and patient education to im-
prove outcomes of care.
Persistent H. pylori Infection
H. pylori is the primary cause of peptic ulcer dis-
ease (17). H. pylori infection is curable with regimens
of multiple antimicrobial agents, but antimicrobial resis-
tance is a leading cause of treatment failure (18). Cur-
rent treatment for H. pylori infections generally includes
two or more antimicrobials (amoxicillin, clarithromycin,
nitroimidazoles, tetracycline, etc.), but treatment fails in
10%–20% of all cases, often because of drug resistance.
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A recent study examined 67 H. pylori isolates
from patients unsuccessfully treated with amoxicillin,
clarithromycin, metronidazole, and levofloxacin. Clar-
ithromycin and metronidazole resistance were identified
in 91% and 82.1% of the isolates, respectively; impor-
tantly, 52 (77.6%) were resistant to both drugs. All 67
isolates were susceptible to amoxicillin and tetracycline.
The choice of antibiotic treatment for refractory H. pylori
infections should be based on in vitro susceptibility data,
and physicians should consider local resistance patterns
when treating these infections empirically (19).
The efficacy of a culture-guided treatment approach
for the eradication of persistent H. pylori infection was
analyzed in 94 consecutive patients in whom H. pylori
infection had persisted after two eradication attempts.
Susceptibility analysis was performed for amoxicillin,
clarithromycin, metronidazole, tetracycline, and lev-
ofloxacin. Patients were then treated with a culture-guided,
third-line regimen: 89 patients with a 1-week quadruple
regimen including omeprazole, bismuth, doxycycline, and
amoxicillin, and 5 patients with a 1-week triple regimen
containing omeprazole, amoxicillin, and levofloxacin or
clarithromycin. Ninety-four subjects (100%) were resis-
tant to metronidazole, 89 (95%) to clarithromycin, 29
(31%) to levofloxacin, and 5 (5%) to tetracycline. No re-
sistance to amoxicillin was found in any patient. Overall,
H. pylori eradication was obtained in 90% of subjects.
The quadruple regimen was effective in 81 patients (92%
by per protocol and 91% by intention-to-treat analysis).
Four patients (80% by both per protocol and intention-
to-treat analysis) were H. pylori-negative after the triple
regimen. This study confirmed that the culture-guided,
third-line therapeutic approach is effective for the eradi-
cation of H. pylori. Furthermore, the 1-week doxycycline-
and amoxicillin-based quadruple regimen is a good third-
line “rescue” treatment option (20).
The Helicobacter pylori Antimicrobial Resistance
Monitoring Program is a prospective, multicenter U.S.
network that tracks national incidence rates of H. pylori
antimicrobial resistance. Of 347 clinical H. pylori isolates
collected from December 1998 to 2002, 101 (29.1%) were
resistant to one antimicrobial agent, and 17 (5%) were
resistant to two or more antimicrobial agents. Eighty-
seven (25.1%) isolates were resistant to metronidazole,
45 (12.9%) to clarithromycin, and 3 (0.9%) to amoxi-
cillin. On multivariate analysis, black race was the only
significant risk factor (P < 0.01; hazard ratio, 2.04) for
infection with a resistant H. pylori strain (21).
Owing to rising drug-resistant H. pylori infections, cur-
rently recommended PPI-based triple therapies are losing
their efficacy, and regimens efficacious in the presence of
drug resistance are needed. A recent meta-analysis exam-
ined the efficacy, safety, and adherence of first-line quadru-
ple H. pylori therapies in adults. Quadruple therapy con-
taining a gastric acid inhibitor, bismuth, metronidazole,
and tetracycline was enhanced when omeprazole was in-
cluded, when treatment duration lasted 10–14 days, and
when therapy took place in the Netherlands, Hong Kong,
and Australia. Treatment efficacy decreased as the preva-
lence of metronidazole resistance increased. Even in areas
with a high prevalence of metronidazole resistance, this
quadruple regimen eradicated more than 85% of H. pylori
infections when it contained omeprazole and was given
for 10–14 days. Furthermore, in the presence of clar-
ithromycin resistance, this quadruple regimen eradicated
90%–100% of H. pylori infections, while the currently
recommended triple therapy containing clarithromycin,
amoxicillin, and a PPI eradicated only 25%–61% (P <
0.001). Adherence and adverse events for quadruple ther-
apy were similar to currently recommended triple thera-
pies. This study questions whether quadruple therapy with
a PPI, a bismuth compound, metronidazole, and tetracy-
cline should be recommended as first-line anti-H. pylori
therapy (22).
In patients who present with persistent or worsening
peptic ulcer disease, it is important to assess for active
H. pylori infection and to determine whether antimicrobial
resistance is present. Bacteriological methods are neces-
sary for detection of the putative antimicrobial resistance
of H. pylori. The main cause for failure of H. pylori erad-
ication therapy is resistance to clarithromycin, which is
due to point mutations. In these patients with resistant
isolates, the provision of alternative therapeutic regimens
for the successful eradication of H. pylori infection is
mandatory.
High-dose PPI/amoxicillin therapy can also be used as
an alternative strategy for retreatment of H. pylori after
failure to eradicate the infection. A recent prospective co-
hort study included 17 H. pylori-positive patients who had
failed to clear H. pylori infection after 1 week of treatment
with usual doses of PPI, amoxicillin, and clarithromycin.
The sensitivity of H. pylori to clarithromycin and amox-
icillin and the CYP2C19 genotype status of each patient
were determined, and treatment with rabeprazole (10 mg
qid) and amoxicillin (500 mg qid) for 2 weeks was started.
Eleven patients were infected with a clarithromycin-
resistant strain of H. pylori. Twelve patients had the
homozygous extensive metabolizer genotype, five had
the heterozygous extensive metabolizer genotype, and
there were none with the poor metabolizer genotype
of CYP2C19. All patients were successfully cleared of
their H. pylori infection without any adverse effects, ir-
respective of CYP2C19 genotype status (100%; 95% CI,
76–100). High-dose dual therapy with rabeprazole (10 mg
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qid) and amoxicillin (500 mg qid) for 2 weeks was a useful
treatment strategy after failure of eradication of H. pylori
by the usual triple PPI/amoxicillin/clarithromycin therapy
(23).
The future development of new anti-H. pylori therapies
presents enormous challenges to clinical pharmacologists,
not only in identifying novel targets, but also in ensuring
adequate drug delivery to the unique gastric mucous niche
of H. pylori. Several lines of evidence from experimen-
tal animal models of infection have clearly demonstrated
the feasibility of a prophylactic and therapeutic vaccine
against H. pylori. However, comparatively few clinical
studies have been carried out to evaluate whether the pos-
itive results obtained in animals can be reproduced in hu-
mans. The preliminary results obtained with single com-
ponent, mucosally delivered vaccines have shown very
limited results thus far. Very good immunogenicity and
safety profiles are now being obtained with parenterally
delivered, aluminium hydroxide-adjuvanted multicompo-
nent candidate vaccines. Improved vaccine formulations,
antigen preparation, adjuvants, and delivery systems have
to be designed and tested for safety and immunogenicity.
These studies are also needed for deciphering those
aspects of the effector immune responses that corre-
late with protection against H. pylori infection and
disease (24).
Non-H. pylori-Related Ulcer
The proportion of ulcers that are not associated with
H. pylori infection is increasing, especially in the United
States and Australia (25). The increase in this type of ul-
cer warrants an analysis of the diagnostic and treatment
approaches to H. pylori-negative ulcers. Review of the
medical literature documents that up to 52% of duode-
nal ulcers and 47% of gastric ulcers are not caused by
H. pylori infection. The cause of H. pylori-negative ul-
ceration appears to be multifactorial. Contributing factors
include covert NSAID use, false-negative H. pylori tests,
genetic predisposition, and, in rare cases, Crohn’s disease
or ZES. H. pylori-negative ulcers tend to be associated
with hypersecretion and can have serious clinical seque-
lae. H. pylori-negative ulcers are often refractory to treat-
ment, and may have an aggressive clinical course, possibly
because they lack the beneficial effect of H. pylori infec-
tion on antisecretory therapy. PPIs appear to effectively
treat both H. pylori-positive and H. pylori-negative ulcers
(26). Furthermore, the recent availability of intravenous
PPIs has simplified therapy in patients that cannot receive
enteral therapy, such as this patient with partial gastric
outlet obstruction and when there is question or concern
for adequate absorption of enteral PPIs.
In patients with hypersecretion as the etiology of the
non-H. pylori-related ulcer, the potential etiologies in-
clude idiopathic gastric hypersecretion or ZES and/or
gastrinoma. The diagnostic evaluation in these patients is
difficult, however, since most of these patients have hyper-
gastrinemia due to chronic treatment with acid suppressive
therapy and medical regimens for eradication of H. pylori.
PPIs are potent acid suppressants which, at normal doses,
can result in hypergastrinemia. In fact, there is a signifi-
cant inverse correlation between the fasting serum gastrin
concentration and the gastric acid profile in patients with
gastroesophageal reflux and peptic ulcer disease. An el-
evated fasting serum gastrin concentration while on PPI
therapy suggests that gastric acid secretion is adequately
suppressed (27). Additionally, gastric outlet obstruction
may be a contributing etiology of elevated serum gastrin.
Therefore, the use of PPIs could delay or mask the di-
agnosis of gastrinoma (28). In this case, an attempt was
made to eliminate PPI therapy as a possible cause of hyper-
gastrinemia, prior to surgical intervention. It was critical
to determine the etiology of the worsening ulcer disease
and hypergastrinemia in this patient. A short course of
high-dose H-2 receptor antagonist therapy was initiated
prior to repeat gastrin measurements. It is important to
note, however, that this strategy is not recommended in
the treatment of acute peptic ulcer disease, since it has
been well established that ulcer healing rates are superior
with PPI therapy (29).
A recent study investigated whether the widespread
use of PPIs masks or complicates the diagnosis of gas-
trinoma. Data from two centers with different referral
criteria for suspected gastrinomas were analyzed (Gas-
troenterology Unit, Rome, Italy, and National Institutes
of Health, Bethesda, MD, USA). The number of referrals
and the number of new patients with gastrinoma diag-
nosed in the years prior to the widespread use of PPIs
(1986–1992) were compared with the numbers since PPIs
became widely available (1993–1998). The decrease in
referral rate (P = 0.0009) and the decrease in the an-
nual rate of gastrinoma diagnosis (P = 0.0020) at both
centers correlated with the increased use of PPIs. At the
Italian center, there was a 62% decrease in annual refer-
rals (P < 0.0001) in the post-PPI period, relative to the
pre-PPI period, whereas there was an increase in the rate
of referral of other GI endocrine tumors. The number of
new cases of gastrinoma diagnosed decreased by 40%.
At the U.S. center, the referral rate decreased by 28%
(P = 0.024) in the post-PPI period. There was also a 43%
decrease in the number of new cases diagnosed annually
in the post-PPI period (P = 0.0012). There was a 2.6-
fold increase in the post-PPI period in the percentage of
referrals with a false diagnosis of gastrinoma as the cause
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of hypergastrinaemia (P = 0.0040). These data support
the conclusion that, since PPIs have been released, the
diagnosis of gastrinoma has been masked and will prob-
ably be delayed, with the result that patients with gastri-
noma will be diagnosed at more advanced stages in their
disease course (30). Physicians must therefore maintain a
high index of suspicion for this disease and not mask a po-
tential malignancy with prolonged control of acid-related
symptoms without taking steps to diagnose gastrinoma.
Furthermore, differentiation of idiopathic gastric hy-
persecretion versus gastrinoma or ZES can be difficult
and frequently requires multiple diagnostic studies. This
workup is necessary, however, since the medical and sur-
gical therapy of these patients differs. Patients with “id-
iopathic” ulcers are characterized by postprandial hyper-
secretion of acid and hypergastrinemia with accelerated
gastric emptying. Any patient with intractable or recur-
rent peptic ulcer disease requires diagnostic evaluation
for ZES or gastrinoma.
ZES is characterized by severe peptic ulcer disease due
to gastric acid hypersecretion that results from gastrin-
secreting tumors (gastrinomas) of the GI tract. Gastrin
stimulates the parietal cell to secrete acid directly and
indirectly by releasing histamine from enterochromaffin-
like cells and induces hyperplasia of parietal and
enterochromaffin-like cells. ZES should be suspected in
patients with severe erosive or ulcerative esophagitis, mul-
tiple peptic ulcers, peptic ulcers in unusual locations, re-
fractory peptic ulcers, complicated peptic ulcers, peptic
ulcers associated with diarrhea, and a family history of
multiple endocrine neoplasia type 1 (MEN-1) or any of the
endocrinopathies associated with MEN-1. In about 75%
of patients the tumors are sporadic, and 25% of patients
have MEN-1. Patients with ZES have two problems that
require treatment—the hypersecretion of gastric acid and
the gastrinoma itself. Although most gastrinomas grow
slowly, 60% to 90% are malignant and 25% show rapid
growth.
The clinical signs and symptoms of patients presenting
with ZES can be myriad. A prospective evaluation of the
initial presenting symptoms in 261 patients with ZES was
performed over a 25-year period at the National Institutes
of Health. Twenty-two percent of the patients had MEN-1
with ZES. Mean age at onset was 41.1 ± 0.7 years, with
MEN-1 patients presenting at a younger age than those
with sporadic ZES (P < 0.0001). A mean delay to diag-
nosis of 5.2 ± 0.4 years occurred in all patients. Abdom-
inal pain and diarrhea were the most common symptoms,
present in 75% and 73% of patients, respectively. Heart-
burn and weight loss, which were uncommonly reported
in early series, were present in 44% and 17% of patients,
respectively. GI bleeding was the initial presentation in a
quarter of the patients. Patients rarely presented with only
one symptom (11%); pain and diarrhea was the most fre-
quent combination, occurring in 55% of patients. An im-
portant presenting sign that should suggest ZES is promi-
nent gastric body folds, which were noted on endoscopy
in 94% of patients; however, esophageal stricture and duo-
denal or pyloric scarring, reported in numerous case re-
ports, were noted in only 4%–10%. A correct diagnosis
of ZES was made by the referring physician initially in
only 3% of the patients. The most common misdiagnoses
made were idiopathic peptic ulcer disease (71%), idio-
pathic gastroesophageal reflux disease (7%), and chronic
idiopathic diarrhea (7%). These results demonstrate that
abdominal pain, diarrhea, and heartburn are the most com-
mon presenting symptoms in ZES and that heartburn and
diarrhea are more common than previously reported. The
presence of weight loss, especially with abdominal pain,
diarrhea, or heartburn, is an important clue suggesting the
presence of gastrinoma. The presence of prominent gastric
body folds, a clinical sign that has not been appreciated,
is another important clue to the diagnosis of ZES. Pa-
tients with MEN-1 presented at an earlier age; however,
in general, the initial symptoms were similar to those of
patients without MEN-1. Gastrinoma extent and location
have minimal effects on the clinical presentation. Overall,
neither the introduction of successful antisecretory ther-
apy nor the widespread publication of information about
ZES, attempting to increase awareness, has shortened the
delay in diagnosis or reduced the incidence of patients
presenting with peptic complications. The introduction of
successful antisecretory therapy, however, has likely led to
patients presenting with less severe symptoms and fewer
complications (31).
The initial diagnostic test for ZES should be a fast-
ing serum gastrin level when antisecretory medications
are discontinued. Patients with ZES have significantly in-
creased serum gastrin concentrations, frequently between
150 and 1000 pg/ml. If the gastrin level is elevated, gastric
acidity should be assessed through pH or gastric analysis.
It should be noted that hypochlorhydria causes feedback
stimulation of antral gastrin secretion. In suspected cases
of ZES with mild hypergastrinemia, the secretin stimula-
tion test may be useful.
Serologic markers helpful in reaching a diagnosis of
gastrinoma are also available, as serum chromogranin A
has been shown to be a general marker for neuroendocrine
tumors. It is elevated in gastrinoma, and the elevation has
been reported to correlate with tumor volume (32). It is
less sensitive and specific than fasting serum gastrin for
the diagnosis of ZES but can be a confirmatory test. Chro-
mogranin A is considered the most accurate marker in
the diagnosis of gastroenteropancreatic (GEP) endocrine
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tumors. Pancreatic polypeptide has also been proposed to
play this role but then not used due to its low sensitivity. A
recent study examined whether the assessment of pancre-
atic polypeptide would improve the diagnostic reliability
of chromogranin A in patients (n = 68) with GEP tumors.
By combining the two markers a significant gain in sensi-
tivity vs. chromogranin A alone was obtained: overall in
GEP tumors (96% vs. 84%; P = 0.04), in nonfunction-
ing (95% vs. 75%; P = 0.02), and in pancreatic (94% vs.
74%; P = 0.04). Therefore, the combined assessment of
both pancreatic polypeptide and chromogranin A leads to
a significant increase in sensitivity in the diagnosis of GEP
tumors (33).
The secretin stimulation test can differentiate patients
with gastrinomas from those with other causes of hy-
pergastrinemia, such as idiopathic gastric hypersecretion.
By an unknown mechanism, gastrinoma cells are respon-
sive to secretin administration, but normal gastric G cells
are actually inhibited by it. A rise in serum gastrin by
200 pg/ml is considered positive and is 90% sensitive and
specific for the presence of gastrinoma. Secretin, however,
is difficult to obtain for the conduct of this diagnostic test.
Calcium infusion has been advocated as a provocative
test for the diagnosis of some endocrine tumors of the
pancreas and GI tract (gastrinoma, insulinoma, intestinal
carcinoids). The release of gastrin from gastrinoma tis-
sue is very sensitive to alterations in the serum calcium
level, and the calcium infusion test is recommended in
ZES when the results of the secretin stimulation test are
equivocal (34).
Initial treatment for ZES should be oral high-dose PPIs.
Maintenance po pantoprazole therapy at a dose of 80–
240 mg/day in divided doses was both effective and gen-
erally well tolerated for patients with ZES (n = 26) and
idiopathic hypersecretion (n = 9) in a recent study (35). If
parenteral therapy is needed, intermittent bolus injection
of pantoprazole is recommended (36).
Imaging for gastrinoma localization can be accom-
plished via computed tomography or magnetic resonance
imaging, but perhaps the best modality with highest sen-
sitivity and specificity for localization is via somatostatin
receptor scintigraphy with 111-In-pentetreotide and spec-
troscopy (37). Somatostatin receptor scintigraphy, which
images the entire body at one time, is more sensitive for de-
tecting gastrinomas than any conventional imaging study
(38). Since this test became available, all liver metastases
detected at exploration have been detected by the test, and
it is therefore the initial localization study of choice. This
study, however, has limited sensitivity for detection of the
primary gastrinoma.
In a recent prospective study, 55 patients with a re-
cent diagnosis of endocrine gastroenteropancreatic tu-
mors (22 intestinal carcinoids, 17 gastrinomas, 10 non-
functioning pancreatic tumors, and 6 insulinomas), were
examined with somatostatin-receptor scintigraphy, com-
puted tomography, and ultrasonography. Results of the
three imaging modalities were compared with findings
at surgical exploration. Of 17 gastrinomas, 9 were de-
tected by somatostatin-receptor scintigraphy, but com-
puted tomography and ultrasonography localized only
7. Metastases from the gastrinoma were localized by
somatostatin-receptor scintigraphy in all cases; computed
tomography and ultrasonography detected metastases in
only 6 of 9 patients. Somatostatin-receptor scintigraphy
is superior to computed tomography and ultrasonography
for determining the extent of the disease in patients with
gastrinomas. However, the problem of detecting primary
tumors in these patients is not solved by somatostatin-
receptor scintigraphy (39). Endoscopic ultrasound may
have a similar sensitivity for identifying primary tumors.
A combination of both somatostatin receptor scintigra-
phy and endoscopic ultrasound detects more than 90% of
gastrinomas.
The role of surgery in patients with the ZES is contro-
versial (40). Total gastrectomy and antisecretory surgery is
rarely required. In patients without metastasis and without
MEN-1, surgical cure is possible in 30%. It has been sug-
gested that patients with gastrinomas larger than 2.5 cm,
irrespective of whether they have MEN-1, should undergo
surgical resection in an effort to decrease the risk for
metastasis (41). A recent study examined the outcomes
of 151 ZES patients who underwent surgical intervention.
Of these patients, 123 had sporadic gastrinomas and 28
had MEN-1 with an imaged tumor of at least 3 cm in
diameter. Tumor localization studies and functional lo-
calization studies were performed routinely. All patients
underwent surgery according to a similar operative pro-
tocol, and all patients who had surgery after 1986 un-
derwent duodenotomy. The 151 patients underwent 180
exploratory operations. The mean (±SD) follow-up af-
ter the first operation was 8 ± 4 years. Gastrinomas were
found in 141 of the patients (93%), including all of the
last 81 patients to undergo surgery. The tumors were lo-
cated in the duodenum in 74 patients (49%) and in the
pancreas in 36 patients (24%); however, primary tumors
were found in lymph nodes in 17 patients (11%) and in
another location in 13 patients (9%). The primary location
was unknown in 24 patients (16%). Among the patients
with sporadic gastrinomas, 34% were free of disease at
10 years, compared with none of the patients with MEN-
1. The overall 10-year survival rate was 94%. This study
concluded that all patients with ZES who do not have
MEN-1 or metastatic disease should be offered surgical
exploration for possible cure (42).
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SEVERE AND REFRACTORY PEPTIC ULCER DISEASE
CONCLUSION
Optimal management of severe or refractory peptic ul-
cer disease requires a multidisciplinary team approach,
utilizing primary care providers, gastroenterologists, and
general surgeons. Medical management has become the
cornerstone of therapy. Identification and eradication of
H. pylori infection combined with acid reduction regimens
can heal ulceration as well prevent recurrence. Severe, in-
tractable, or recurrent peptic ulcer disease and associated
complications mandate a careful and methodical evalua-
tion and management strategy to determine the potential
etiologies and necessary treatment (medical or surgical)
required.
REFERENCES
1. Soll AH: Medical treatment of peptic ulcer disease. JAMA 275:622,
1996
2. Walsh JH, Peterson WL: The treatment of Helicobacter pylori
infection in the management of peptic ulcer disease. N Engl J
Med333:984, 1995
3. Hopkins RJ, Girardi LS, Turney EA: Relationship between H. pylori
eradication and reduced duodenal and gastric ulcer recurrence: A
review. Gastroenterology 110:1244, 1996
4. Verma S, Giaffer MH: Helicobacter pylori eradication ameliorates
symptoms and improves quality of life in patients on long-term acid
suppression. a large prospective study in primary care. Dig Dis Sci
47(7):1567–1574, 2002
5. Bardhan KD, Nayyar AK, Royston C: History in our lifetime:
the changing nature of refractory duodenal ulcer in the era of
histamine H2 receptor antagonists. Dig Liver Dis 35(8):529–536,
2003
6. Ford A, Delaney B, Forman D, Moayyedi P: Eradication therapy
for peptic ulcer disease in Helicobacter pylori positive patients.
Cochrane Database Syst Rev (4):CD003840, 2004
7. Liu CC, Lee CL, Chan CC, Tu TC, Liao CC, Wu CH, Chen TK:
Maintenance treatment is not necessary after Helicobacter pylori
eradication and healing of bleeding peptic ulcer: a 5-year prospec-
tive, randomized, controlled study. Arch Intern Med 163(17):2020–
2024, 2003
8. Bardhan KD, Williamson M, Royston C, Lyon C: Admission rates
for peptic ulcer in the trent region, UK, 1972–2000. changing pat-
tern, a changing disease? Dig Liver Dis 36(9):577–588, 2004
9. Miwa H, Sakaki N, Sugano K, Sekine H, Higuchi K, Uemura
N, Kato M, Murakami K, Kato C, Shiotani A, Ohkusa T, Takagi
A, Aoyama N, Haruma K, Okazaki K, Kusugami K, Suzuki M,
Joh T, Azuma T, Yanaka A, Suzuki H, Hashimoto H, Kawai T,
Sugiyama T: Recurrent peptic ulcers in patients following success-
ful Helicobacter pylori eradication: a multicenter study of 4940 pa-
tients. Helicobacter 9(1):9–16, 2004
10. Lanas AI, Remacha B, Esteva F, et al.: Risk factors associated with
refractory peptic ulcers. Gastroenterology 109:1124, 1995
11. Rosenstock S, Jorgensen T, Bonnevie O, Andersen L: Risk factors
for peptic ulcer disease: a population based prospective cohort study
comprising 2416 Danish adults. Gut 52(2):186–193, 2003
12. Anda RF, Williamson DF, Escobedo LG, Remington PL: Smoking
and the risk of peptic ulcer disease among women in the United
States. Arch Intern Med 150(7):1437–1441, 1990
13. Reynolds JC, Schoen RE, Maislin G, Zangari GG: Risk factors for
delayed healing of duodenal ulcers treated with famotidine and ran-
itidine. Am J Gastroenterol 89(4):571–580, 1994
14. Laine L: Proton pump inhibitor co-therapy with nonsteroidal anti-
inflammatory drugs-nice or necessary? Rev Gastroenterol Disord 4
(Suppl 4):S33–S41, 2004
15. Goldstein JL: Challenges in managing NSAID-associated gastroin-
testinal tract injury. Digestion 69 (Suppl 1):25–33, 2004
16. Lai KC, Lam SK, Chu KM, Hui WM, Kwok KF, Wong BC, Hu
HC, Wong WM, Chan OO, Chan CK: Lansoprazole reduces ulcer
relapse after eradication of Helicobacter pylori in nonsteroidal anti-
inflammatory drug users—a randomized trial. Aliment Pharmacol
Ther 18(8):829–836, 2003
17. Goddard AF, Logan RP: Diagnostic methods for Helicobacter pylori
detection and eradication. Br J Clin Pharmacol 56(3):273–283, 2003
18. Howden CW, Hunt RH: Guidelines for the management of
Helicobacter pylori infection. Ad Hoc Committee on Practice
Parameters of the American College of Gastroenterology. Am J
Gastroenterol 93(12):2330–2338, 1998
19. Branca G, Spanu T, Cammarota G, Schito AM, Gasbarrini A, Gas-
barrini GB, Fadda G: High levels of dual resistance to clarithromycin
and metronidazole and in vitro activity of levofloxacin against He-
licobacter pylori isolates from patients after failure of therapy. Int J
Antimicrob Agents 24(5):433–438, 2004
20. Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista
EC, Cazzato A, Cannizzaro O, Miele L, Grieco A, Gasbarrini
A, Gasbarrini G: High efficacy of 1-week doxycycline- and
amoxicillin-based quadruple regimen in a culture-guided, third-line
treatment approach for Helicobacter pylori infection. Aliment Phar-
macol Ther 19(7):789–795, 2004
21. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman
C, Sulka A, Swaminathan B, Taylor T, Hoekstra M, Griffin P, Smoot
D, Peek R, Metz DC, Bloom PB, Goldschmidt S, Parsonnet J,
Triadafilopoulos G, Perez-Perez GI, Vakil N, Ernst P, Czinn S,
Dunne D, Gold BD: Antimicrobial resistance incidence and risk
factors among Helicobacter pylori-infected persons, United States.
Emerg Infect Dis 10(6):1088–1094, 2004
22. Fischbach LA, Zanten SV, Dickason J: Meta-analysis: the efficacy,
adverse events, and adherence related to first-line anti-Helicobacter
pylori quadruple therapies. Aliment Pharmacol Ther 20(10):1071–
1082, 2004
23. Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura
M, Ohashi K, Ishizaki T: High-dose rabeprazole/amoxicillin ther-
apy as the second-line regimen after failure to eradicate H. pylori by
triple therapy with the usual doses of a proton pump inhibitor, clar-
ithromycin and amoxicillin. Hepatogastroenterology 50(54):2274–
2248, 2003
24. Ruggiero P, Peppoloni S, Rappuoli R, Del Giudice G: The quest for
a vaccine against Helicobacter pylori: how to move from mouse to
man? Microbes Infect 5(8):749–756, 2003
25. Freston JW: Helicobacter pylori-negative peptic ulcers: frequency
and implications for management. J Gastroenterol 35 (Suppl 12):29–
32, 2000
26. Freston JW: Review article: role of proton pump inhibitors in non-
H. pylori-related ulcers. Aliment Pharmacol Ther 15 (Suppl 2):2–5,
2001
27. Bonapace ES, Fisher RS, Parkman HP: Does fasting serum gas-
trin predict gastric acid suppression in patients on proton-pump in-
hibitors? Dig Dis Sci 45(1):34–39, 2000
28. Ellison EC, Sparks J: Zollinger-Ellison syndrome in the era of effec-
tive acid suppression: Are we unknowlingly growing tumors? Am J
Surg 186(3):245–248, 2003
Digestive Diseases and Sciences, Vol. 50, No. 11 (November 2005) 2007
GUZZO ET AL.
29. Kaneko E, Hoshihara Y, Sakaki N, Harasawa S, Ashida K, Asaka M,
Asaki S, Nakamura T, Kobayashi K, Kajiyama G, Ogawa N, Yao T,
Muto Y, Nakazawa S, Takemoto T: Peptic ulcer recurrence during
maintenance therapy with H2-receptor antagonist following first-
line therapy with proton pump inhibitor. J Gastroenterol 35(11):824–
831, 2000
30. Corleto VD, Annibale B, Gibril F, Angeletti S, Serrano J, Venzon DJ,
Delle Fave G, Jensen RT: Does the widespread use of proton pump
inhibitors mask, complicate and/or delay the diagnosis of Zollinger-
Ellison syndrome? Aliment Pharmacol Ther 15(10):1555–1561,
2001
31. Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P,
Doppman JL, Gibril F, Jensen RT: Zollinger-Ellison syndrome. Clin-
ical presentation in 261 patients. Medicine (Baltimore) 79(6):379–
411, 2000
32. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH,
Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts
SW: Chromogranin A as serum marker for neuroendocrine neopla-
sia: comparison with neuron-specific enolase and the alpha-subunit
of glycoprotein hormones. J Clin Endocrinol and Metab 82(8):2622–
2628, 1997
33. Panzuto F, Severi C, Cannizzaro R, Falconi M, Angeletti S, Pasquali
A, Corleto VD, Annibale B, Buonadonna A, Pederzoli P, Delle
Fave G: Utility of combined use of plasma levels of chromogranin
A and pancreatic polypeptide in the diagnosis of gastrointestinal
and pancreatic endocrine tumors. J Endocrinol Invest 27(1):6–11,
2004
34. Wada M, Komoto I, Doi R, Imamura M: Intravenous calcium in-
jection test is a novel complementary procedure in differential
diagnosis for gastrinoma. World J Surg 26(10):1291–1296, 2002
(epub 9/4/02)
35. Metz DC, Soffer E, Forsmark CE, Cryer B, Chey W, Bochenek W,
Pisegna JR: Maintenance oral pantoprazole therapy is effective for
patients with Zollinger-Ellison syndrome and idiopathic hypersecre-
tion. Am J Gastroenterol 98(2):301–307, 2003
36. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin
IM, Walsh JH, Beg M, Bochenek W, Metz DC: Intravenous pan-
toprazole rapidly controls gastric acid hypersecretion in patients
with Zollinger-Ellison syndrome. Gastroenterology 118(4):696–
704, 2000
37. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ,
Termanini B, Weber HC, Stewart CA, Jensen RT: Somatostatin
receptor scintigraphy: its sensitivity compared with that of other
imaging methods in detecting primary and metastatic gastrinomas.
A prospective study. Ann Intern Med 125(1):26–34, 1996
38. Gibril F, Reynolds JC, Doppman JL, et al.: Somatostatin recep-
tor scintigraphy: its sensitivity compared with that of other imaging
methods in detecting primary and metastatic gastrinomas: a prospec-
tive study. Ann Intern Med 125:26–34, 1996
39. Kisker O, Bartsch D, Weinel RJ, Joseph K, Welcke UH, Zaraca
F, Rothmund M: The value of somatostatin-receptor scintigraphy
in newly diagnosed endocrine gastroenteropancreatic tumors. J Am
Coll Surg 184(5):487–492, 1997
40. Norton JA, Jensen RT: Resolved and unresolved controversies in the
surgical management of patients with Zollinger-Ellison syndrome.
Ann Surg 240(5):757–773, 2004
41. Hung PD, Schubert ML, Mihas AA: Zollinger-Ellison syn-
drome.Curr Treat Opt Gastroenterol 6(2):163–170, 2003
42. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL,
Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F, Jensen RT:
Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med
341(9):635–644, 1999
2008 Digestive Diseases and Sciences, Vol. 50, No. 11 (November 2005)
